Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing the first-in-class pro-resolving drug LAU-7b, today announces that it has completed the enrollment for its placebo-controlled Phase 2 RESOLUTION clinical study of…
Announces Positive Outcome of Pre-Planned Interim DSMB Safety Review and Futility Analysis for Phase 2 RESOLUTION Study in Hospitalized COVID-19 PatientsCompletes Enrollment in Phase 2 APPLAUD Study in Patients with…
The Phase 2 study aims to evaluate the dual antiviral and inflammation-controlling effects of the company’s LAU-7b oral drug candidate against COVID-19 infectionLaurent Pharmaceuticals Inc., a Montreal-based biopharmaceutical company, today…